Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 1, 2009

View Archived Issues

Improvements in bone seen with anti-sclerostin antibody treatments in experimental models

Snapshots: Recent clinical data on denosumab from the ASBMR meeting

Eisai submits application in Japan for additional indication for Pariet in nonerosive GERD

Cell Therapeutics applies for European orphan drug designation for pixantrone in NHL

Kyorin and Eisai sign license agreement for Uritos for overactive bladder

ThromboGenics completes enrollment in phase III TG-MV-006 trial of microplasmin

Multikinase inhibitor regorafenib shows promising antitumor activity in phase II trial in RCC

Arasertaconazole nitrate displays potent antifungal/antibacterial activity in vitro and in vivo

Promising phase I and II clinical data on NGR-hTNF in solid tumors disclosed at ECCO/ESMO

5-HT6 receptor ligands for the treatment of schizophrenia presented by Pfizer

Palumed and CNRS describe a new hybrid antibacterial, Vancomyquine PA-1409

Onyx initiates enrollment in phase I study of ONX-0801 in advanced solid tumors

Synta initiates phase I/II clinical study of STA-9090 in hematologic malignancies

New CVDefine biomarker kit for cardiovascular disease available in North America

Volcano reports VH IVUS imaging results from acute coronary syndrome study

Raptor Pharmaceuticals and TorreyPines Therapeutics merge

Novel ERbeta ligands in early development at GSK for the treatment of pain

Vildagliptin analogue PKF-275-055 improves experimental diabetic neuropathy

GlaxoSmithKline's Pandemrix H1N1 vaccine approved in Europe

Amira Pharmaceuticals claims novel CRTH2 antagonists for the treatment of asthma

Sosei submits NDA for emergency contraceptive pill NorLevo in Japan

Abbott and Eisai apply for Japanese approval of Humira for Crohn's disease

PolyMedix begins dosing in phase Ib clinical trial of anticoagulant reversing PMX-60056

E.C. approves Novartis' Focetria vaccine for use in the H1N1 influenza pandemic

Roche initiates dosing in phase II trial of PLX-4032 in metastatic melanoma

Novartis reports initial results from phase III study of FTY-720 in multiple sclerosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...